CC
GRCL

Cannell Capital’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Cannell Capital’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,299
Closed -$26.6K – 94
2023
Q1 		$26.6K Hold
14,299
– – 0.01% 82
2022
Q4 		$32.9K Hold
14,299
– – 0.01% 77
2022
Q3 		$46K Buy
14,299
+12,110
+553% +$39.4K 0.01% 69
2022
Q2 		$12K Buy
+2,189
New +$6.81K ﹤0.01% 73

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cannell Capital's GRCL Position: Q2 2023 in Review

Cannell Capital sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q2 2023, closing a stake of 14,299 shares — an estimated $26.6K sold.

Cannell Capital first reported a position in GRCL in Q2 2022 and held it in 4 quarters. The position peaked at $46K in Q3 2022. 36 funds tracked by Wall St. Rank hold GRCL as of Q2 2023.

  • Cannell Capital reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q2 2023 after selling out during the quarter.
  • Cannell Capital sold 14,299 Gracell Biotechnologies Inc. American Depositary Shares shares in Q2 2023, an estimated $26.6K.
  • Cannell Capital first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q2 2022 and held it in 4 quarters.
  • Cannell Capital's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $46K in Q3 2022.
  • 36 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q2 2023.

Based on Cannell Capital's 13F filing for Q2 2023, filed 14 Aug 2023.